Pfizer Pharmaceuticals, Inc.
Attention: Mary Pias, Regulatory Strategist
445 Eastern Point Road
Groton, CT 06340

Dear Ms. Pias:

Please refer to your Supplemental New Drug Applications (sNDA) dated April 26, 2013 (NDA 20699/S-103) and June 12, 2014 (NDA 20699/S-105), submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act (FDCA) for Effexor XR (venlafaxine hydrochloride) 37.5 mg, 75 mg, and 150 mg extended-release tablets.

We acknowledge receipt of your amendment dated May 2, 2014.

We also refer to our letter dated May 13, 2014, notifying you, under Section 505(o)(4) of the FDCA, of new safety information that we believe should be included in the labeling for drugs to treat major depressive disorder. This information pertains to the risk of angle-closure glaucoma.

Your May 2, 2014, amendment constituted a complete response to our action letter dated December 20, 2013.

These supplemental applications propose the following changes:

**NDA 20699/S-105**
This supplemental new drug application provides for revisions to the labeling for Effexor XR consistent with our May 13, 2014 letter.

**NDA 20699/S-103**
This supplemental new drug application proposes revisions to the Abnormal Bleeding subsection to the Precautions section.

**APPROVAL & LABELING**

We have completed our review of these supplemental applications. They are approved, effective on the date of this letter, for use as recommended in the enclosed, agreed-upon labeling text.
We note that your June 12, 2014, submission includes final printed labeling (FPL) for your package insert and Medication Guide. We have not reviewed this FPL. You are responsible for assuring that the wording in this printed labeling is identical to that of the approved content of labeling in the structured product labeling (SPL) format.

**CONTENT OF LABELING**

As soon as possible, but no later than 14 days from the date of this letter, submit the content of labeling [21 CFR 314.50(l)] in structured product labeling (SPL) format using the FDA automated drug registration and listing system (eLIST), as described at [http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm](http://www.fda.gov/ForIndustry/DataStandards/StructuredProductLabeling/default.htm). Content of labeling must be identical to the enclosed labeling (text for the package insert, and Medication Guide), with the addition of any labeling changes in pending “Changes Being Effected” (CBE) supplements, as well as annual reportable changes not included in the enclosed labeling.


The SPL will be accessible from publicly available labeling repositories.

Also within 14 days, amend all pending supplemental applications for this NDA, including CBE supplements for which FDA has not yet issued an action letter, with the content of labeling [21 CFR 314.50(l)(1)(i)] in MS Word format, that includes the changes approved in this supplemental application, as well as annual reportable changes and annotate each change. To facilitate review of your submission, provide a highlighted or marked-up copy that shows all changes, as well as a clean Microsoft Word version. The marked-up copy should provide appropriate annotations, including supplement number(s) and annual report date(s).

**REPORTING REQUIREMENTS**

We remind you that you must comply with reporting requirements for an approved NDA (21 CFR 314.80 and 314.81).
If you have any questions, CDR Kofi Ansah, Pharm.D., Senior Regulatory Project Manager, at (301) 796-4158 or email: Kofi.Ansah@fda.hhs.gov.

Sincerely,

{See appended electronic signature page}

Mitchell V. Mathis, M.D.
CAPT, USPHS
Director
Division of Psychiatry Products
Office of Drug Evaluation I
Center for Drug Evaluation and Research

ENCLOSURE: Content of Labeling
This is a representation of an electronic record that was signed electronically and this page is the manifestation of the electronic signature.

/s/

MITCHELL V Mathis
07/07/2014